The Vercise Neural Navigator 5 Software with STIMVIEW XT Technology. Credit: Boston Scientific Corporation.

The US Food and Drug Administration (FDA) has granted approval for Boston Scientific’s Vercise Neural Navigator 5 Software for deep brain stimulation (DBS).

Utilised as a component of the Vercise Genus DBS systems, the software provides clinicians with actionable data for efficiently programming treatment for individuals with essential tremor or Parkinson’s disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The fourth-generation Vercise Genus DBS system helps deliver targeted electrical stimulation through leads that are surgically implanted in the brain and connected to implantable pulse generators for treating Parkinson’s disease and essential tremor symptoms.

Featuring STIMVIEW XT technology, the new software is the newest inclusion in the company’s integrated portfolio of image-guided programming solutions for its DBS system.

Created in collaboration with BrainLAB, these tools have shown a 56% reduction in programming time and deliver real-time visualisation and stimulation of the brain anatomy of each person.

The enhanced user interface of the Vercise Neural Navigator 5 Software showcases data related to a patient in a simplified format and helps clinicians access advanced settings for improved delivery of therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, the software offers flexibility for better management of increasing requirements of individual patients at any stage of their condition.

Boston Scientific Neuromodulation president Jim Cassidy said: “Developing meaningful tools to help physicians provide personalised treatments for their patients delivers on our promise to advance our technologies for people living with neurological conditions.

“Providing effective DBS therapy is complex and can be time-consuming. This software will help streamline the process and allow for more doctor-patient interaction time.”

In February this year, Boston Scientific secured 510(k) clearance from the FDA for its LithoVue Elite Single-Use Digital Flexible Ureteroscope System.